SHARNICE ADAMS: Open Payments
NPI 1255059812 · SAGINAW, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$803 in 39 payments from 17 companies in 2025. Trend: 2023 $45 · 2024 $274 · 2025 $803
Food & beverage: $703Education: $100
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 4 | $148 |
| AstraZeneca Pharmaceuticals LP | 6 | $98 |
| PFIZER INC. | 4 | $79 |
| Novo Nordisk Inc | 4 | $72 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Merck Sharp & Dohme LLC | 3 | $54 |
| Neurocrine BioSciences, Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $40 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
Products named: Auvelity, ELIQUIS, AIRSUPRA, Veozah, INGREZZA, Kerendia, Wegovy, VERQUVO.
Industry payments across MI — which companies pay providers there.
